Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Chemotherapy and ASCT for Intestinal T-cell Lymphoma
NCT00669812Phase 2Unknown
- Sponsor
- Cancer Research UK
- Start
- Feb 2008
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ifosfamide, epirubicin, etoposide and methotrexate in intestinal T-cell lymphoma (ITCL), sponsored by Cancer Research UK. Primary endpoints: Survival at 1 year and Toxicity. Status: unknown.
02
Drugs
ifosfamideepirubicinetoposidemethotrexate
03
Conditions
intestinal T-cell lymphoma (ITCL)
Beyond the preview
Go deeper on NCT00669812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00669812.